Daraxonrasib nearly doubles survival rates for patients battling advanced pancreatic cancer
Category: Health
In a historic move for cancer treatment, the U.S. Food and Drug Administration (FDA) has approved daraxonrasib, a new drug that offers renewed hope to patients battling metastatic pancreatic cancer. Marketed under the brand name Rasonque by Revolution Medicines, this drug has been shown to nearly double the median survival time for patients compared to traditional chemotherapy, a breakthrough that could change the course of treatment for one of the deadliest cancers.
On August 26, 2026, the FDA announced the expedited approval of daraxonrasib, which was granted months ahead of schedule. According to clinical trial results, patients taking the drug experienced a median survival of 13.2 months, significantly higher than the 6.7 months seen with standard chemotherapy. This approval comes as a relief for many, especially those like former Nebraska Senator Ben Sasse, who has publicly shared his struggles with stage IV pancreatic cancer and his participation in clinical trials involving the drug.
The FDA's approval of daraxonrasib marks a turning point in the treatment of pancreatic cancer, which has historically been resistant to many therapies. The drug targets the mutated RAS proteins, which are key drivers of tumor growth in over 90% of pancreatic cancer cases. This innovative approach has been a long time coming, as scientists have struggled for decades to develop a treatment that effectively inhibits these proteins.
Dr. Kyle Diamantas, the Acting FDA Commissioner, emphasized the significance of this approval, stating, "Today’s approval provides a critically new option for patients facing an extraordinarily difficult and historically hard-to-treat cancer. It is our fundamental duty to deliver more cures and meaningful treatments to patients as quickly as possible." He expressed pride in the FDA team that worked diligently to bring this drug to market.
Daraxonrasib works by blocking the activity of mutated RAS proteins, which act like a stuck accelerator in cancer cells, driving their unchecked growth. This mechanism is particularly important for pancreatic cancer, where traditional treatments have often failed. Clinical trials involving 500 patients demonstrated that daraxonrasib improved survival rates and provided a new avenue for potential treatments for other cancers driven by similar mutations, such as colorectal and lung cancer.
Dr. Nicholas Hornstein, a medical oncologist, noted the remarkable nature of the trial results, stating, "This is life-altering. Not just for patients, as far as helping them extend their lives beyond anything we’d ever seen, but for us as physicians, to be able to have a different conversation than we’ve had for so long." The enthusiasm surrounding the drug was evident at a recent cancer research conference, where the trial findings were met with a standing ovation.
The approval of daraxonrasib is particularly impactful considering the grim statistics associated with pancreatic cancer. It is the third leading cause of cancer deaths in the United States, with only about 13% of patients surviving five years after diagnosis. In 2026 alone, the American Cancer Society estimates that approximately 67,000 new cases will be diagnosed, with over 52,000 deaths expected.
Ben Sasse, who was diagnosed with stage IV pancreatic cancer just before Christmas in 2025, has been vocal about the challenges he faced and the hope that daraxonrasib has provided. He reported that the drug significantly reduced his tumor volume by 76% and improved his quality of life, allowing him more time with his family. "I take it orally, but it’s a nasty drug," he shared, describing the severe skin reactions he experienced. Nonetheless, he remains optimistic about the drug’s potential, saying, "It’s giving me more time to be with my family."
Like many cancer treatments, daraxonrasib is not without side effects. Patients have reported issues such as skin toxicity, rash, diarrhea, and fatigue. Dr. Hornstein acknowledged that the severity of these side effects can vary, but he assured that strategies are being developed to mitigate them effectively. The drug’s approval is based on its ability to provide a meaningful extension of life, but it does not cure the disease.
The future looks promising for daraxonrasib as additional trials are underway to explore its efficacy in combination with other treatments, including chemotherapy and immunotherapy. Dr. Mark Goldsmith, CEO of Revolution Medicines, expressed hope that this approval will pave the way for more innovative therapies targeting KRAS mutations across various cancer types.
The drug is priced at approximately $39,800 for a 30-day supply, but most costs are expected to be covered by insurance, making it more accessible to patients who need it. With over 2,000 patients having received early access through an expanded access program, the drug is already making a difference in the lives of many.
| Parameter | Daraxonrasib (Rasonque) | Standard Chemotherapy |
|---|---|---|
| Median Survival Time | 13.2 months | 6.7 months |
| Targeted Protein | Mutated RAS | None |
| Monthly Cost | $39,800 | Varies |
| Side Effects | Skin rash, diarrhea, fatigue | Nausea, hair loss, fatigue |
As the medical community anticipates the full impact of daraxonrasib, many are hopeful that this drug will improve the lives of pancreatic cancer patients and inspire new research and therapies for various cancers driven by similar mechanisms. The approval of Rasonque is a monumental step forward in the fight against pancreatic cancer, providing a glimmer of hope where there was once despair.